CRISPR interference identifies vulnerable cellular pathways with bactericidal phenotypes in Mycobacterium tuberculosis
Matthew B. McNeiliD, Laura M. KeighleyiD, Josephine R. Cook, Chen‐Yi CheungiD, Gregory Murray CookiD
Abstract
Mycobacterium tuberculosis remains a leading cause of death for which new drugs are needed. The identification of drug targets has been advanced by high-throughput and targeted genetic deletion strategies. Each though has limitations including the inability to distinguish between levels of vulnerability, lethality and scalability as a molecular tool. Using mycobacterial CRISPR interference in combination with phenotypic screening we have overcome these individual issues to investigate essentiality, vulnerability and lethality for 96 target genes from a diverse array of cellular pathways, many of which are potential antibiotic targets. Essential genes involved in cell wall synthesis and central cellular functions were equally vulnerable and often had bactericidal consequences. Conversely, essential genes involved in metabolism, oxidative phosphorylation or amino acid synthesis were less vulnerable to inhibition and frequently bacteriostatic. In conclusion, this study provides novel insights into mycobacterial genetics and biology that will help to prioritise potential drug targets.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 33
- FWCI
- 2.06
- Field percentile
- top 10%
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- High-throughput genetic interaction analysis in Mycobacterium tuberculosis identifies highly synergistic drug targets
Cassandra L. Chapman, XinYue Wang, … Matthew McNeil·bioRxiv·Oct 15, 2026
- The phenotypic landscape of the mycobacterial cell
Nadia Herrera, Horia Todor, … Carol A. Gross·bioRxiv·Nov 14, 2025
- Illuminating host-mycobacterial interactions with functional genomic screening to inhibit mycobacterial pathogenesis
Y. Lai, G. H. Babunovic, … T. K. Lu·bioRxiv·Mar 30, 2020
- A chemical-genetic map of the pathways controlling drug potency in Mycobacterium tuberculosis
S. Li, N. C. Poulton, … J. M. Rock·bioRxiv·Nov 27, 2021
- CRISPRi-mediated validation of candidate Myocobacterium abscessus drug targets during host infection
Rashmi Gupta, Breven S. Simcox, Kyle H. Rohde·bioRxiv·Dec 17, 2025
- A multiplexed, target-based phenotypic screening platform using CRISPR interference in Mycobacterium abscessus
Donavan Marcus Neo, Ishay Ben-Zion, … Deborah Tan Hung·ACS Infectious DiseasesPeer-reviewed·Oct 27, 2025